Nicklas Westerholm, Egetis Therapeutics CEO

Ac­qui­si­tion talks on­go­ing for Swedish rare dis­ease biotech Egetis, shares up al­most 40%

Shares of the Swe­den-based rare dis­ease biotech Egetis Ther­a­peu­tics sky­rock­et­ed on Thurs­day af­ter­noon as the com­pa­ny said it’s en­gaged in “on­go­ing dis­cus­sion” with ex­ter­nal par­ties re­gard­ing a “po­ten­tial ac­qui­si­tion.”

Egetis con­firmed ru­mors with a state­ment on Thurs­day while not­ing that there is no cer­tain­ty that a takeover of­fer will be made.

Nonethe­less, the pos­si­bil­i­ty of an ac­qui­si­tion has shot up Egetis’ share price. By the af­ter­noon on Thurs­day, its stock price was {$EGTX.ST} up over 38%. An Egetis spokesper­son told End­points News in an email that it has no fur­ther com­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.